TC
MACK

TFS Capital’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

TFS Capital’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-23,886
Closed -$1.6M – 1049
2015
Q3 		$1.6M Buy
+23,886
New +$1.95M 0.15% 220
2015
Q2 		– Sell
-3,302
Closed -$309K – 1216
2015
Q1 		$309K Sell
3,302
-57,211
-95% -$4.87M 0.03% 667
2014
Q4 		$5.38M Buy
+60,513
New +$4.41M 0.51% 11

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

TFS Capital's MACK Position: Q4 2015 in Review

TFS Capital sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2015, closing a stake of 23,886 shares — an estimated $1.6M sold.

TFS Capital first reported a position in MACK in Q4 2014 and held it in 3 quarters. The position peaked at $5.38M in Q4 2014. 139 funds tracked by Wall St. Rank hold MACK as of Q4 2015.

  • TFS Capital reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • TFS Capital sold 23,886 Merrimack Pharmaceuticals, Inc. shares in Q4 2015, an estimated $1.6M.
  • TFS Capital first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 3 quarters.
  • TFS Capital's Merrimack Pharmaceuticals, Inc. position peaked at $5.38M in Q4 2014.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2015.

Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.